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ABSTRACT 
A simple, selective, rapid, precise, economical, reproducible and stability-indicating UV spectrophotometric method has been developed and validated for 
determination  of  Satranidazole in  pure  form  and  pharmaceutical  dosage  form.  From  solvent  effect  studies  and  the  spectral  behaviour  of  Satranidazole, 
methanol was selected as solvent. The UV spectrum was scanned between 200 to 400 nm and 318 nm was selected as maximum wavelength for absorption. 
Beer’s law was obeyed in the concentration range of 2-30 µg /mL. The regression coefficient was 0.999. The method was validated for accuracy, precision, 
specificity and robustness, in accordance  with  ICH  guidelines. Recovery studies gave  satisfactory results indicating that none of common additives and 
excipients or the degraded impurities interfere in the assay method. Statistical analysis proved the method was precise, reproducible, selective, specific, and 
accurate for analysis of Satranidazole. Stability testing study includes the effect of oxidation, photolysis and susceptibility to hydrolysis across a wide range of 
pH values. The wide linearity range, accuracy and easy preparation of diluent imply the method is suitable for routine quantification of Satranidazole in the 
quality control of bulk forms and pharmaceutical dosage forms with high precision and accuracy.  
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INTRODUCTION 
Satranidazole,  a  novel  nitroimidazole  possessing  a  C-N 
linkage  at  C2  of  the  imidazole  ring  has  been  examined 
(during reduction), for its ability to damage DNA. The drug 
produces  extensive  DNA  damage  characterized  by  helix 
destabilization  and  strand  breakage.  Its  comparison  with 
other  2-  and  5-nitroimidazoles  indicates  it  may  be  more 
active towards anaerobes than many 5-nitroimidazoles. It is 
due to its relatively high redox potential which may make it 
more  resistant  to  inactivation  by  oxygen
1.  It  is  a  highly 
potent,  well-tolerated,  and  clinically  useful  agent  against 
common protozoa. It is rapidly absorbed and exhibits higher 
plasma  and  liver  concentration  than  metronidazole. 
Satranidazole  (SAT)  is  not  included  in  any  official 
pharmacopoeias such as IP, USP and BP. Chemically, it is 3-
(1-methyl-5-nitroimidazol-2-yl)-1-(methylsulfonyl) 
imidazolidin-2-one. Its molecular formula is C8H11N5O5S and 
molecular weight is 289.26. The structure of active moiety is 
mentioned  in  Figure.1.  Literature  survey  revealed  an 
electron-capture  gas  chromatographic  assays  in  blood
2, 
spectrophotometric  methods
3,4,5,6,  HPTLC  methods
7,8  and 
HPLC  methods
9,10,11,12  in  pharmaceutical  dosage  form  for 
estimation  of  Satranidazole  individually  as  well  as  in 
combination  with  Ofloxacin.
  Spectrophotometric  method  is 
generally preferred especially by small-scale industries as the 
cost of the equipment is less and the maintenance problems 
are minimal. The method of analysis is based on measuring 
the  absorption  of  a  monochromatic  light  by  colorless 
compounds  in  the  ultraviolet  path  of  spectrum  i.e.  200  to 
400nm
13.  So  an  attempt  has  been  made  to  develop  a  new 
stability  indicating  UV  spectrophotometric  method  for  its 
estimation  in  pharmaceutical  dosage  form  with  good 
accuracy, precision and simplicity. 
Stability  indicating  assay  methods  (SIAMs)  is  defined  as 
validated quantitative analytical methods that can detect the 
changes  with  time  in  the  chemical,  physical  or 
microbiological  properties  of  the  drug  substance  and  drug 
product, and that are specific so that the contents of active 
ingredient,  degradation  products,  and  other  components  of 
interest can be accurately measured without interference. The 
United States Pharmacopoeia (USP) has a requirement listed 
under ‘Stability Studies in Manufacturing’, which says that 
samples of the products should be assayed for potency by the 
use of a stability-indicating assay. The requirement in such a 
clear  and  detailed  manner  is,  however,  absent  in  other 
pharmacopoeias. The method was validated according to the 
ICH guidelines
14,15,16. 
 
MATERIALS AND METHODS 
Chemicals 
All the chemicals and reagents used were of analytical grade. 
Distilled  water  was  obtained  using  millipore  water 
purification system. Working standard of satranidazole with 
potency of 99.67 % was obtained from Alkem Laboratories 
Limited, Baddi. Commercial tablets containing Satranidazole 
(Satrogyl-300mg) were procured from the local chemist shop. 
All  volumetric  glass-ware  was  pre-calibrated  by  the 
manufacturer  (Borosil)  and  was  of  grade  A.  Aqueous 
solutions of hydrochloric acid, sodium hydroxide, hydrogen 
peroxide were prepared in the usual way. 
 
Instrumentation 
A  PC  based  Shimadzu  1700  UV-Visible  double  beam 
spectrophotometer  with  spectral  band-width  of  1.8  nm, 
wavelength  accuracy  of  2nm  and  two  matched  quartz 
cuvettes of 10 mm optical path length was used along with 
UV Probe software. Another instrument used was Systronics 
UV-VIS  spectrophotometer  Type  118  single  beam  with 
spectral band width of 3nm. 
 
Method Development 
Different solvents were investigated to develop a suitable UV 
spectrophotometric method for the analysis of satranidazole 
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the  drug,  easiness  of  the  sample  preparation,  maximum 
absorbance  and  specificity  of  the  method.  Methanol  was 
selected as the diluent because of the total solubilization of 
the drug in this solvent. The cut off wavelength of methanol 
is  205nm  hence  it  will  not  interfere  in  the  absorption  of 
wavelength in the UV range. 
 
Standard solution preparation 
Standard stock solution was prepared by dissolving 10 mg of 
satranidazole API  in 8.0 ml of methanol in 10 ml volumetric 
flask.  It  was  sonicated  for  15  minutes  with  occasional 
swirling, cooled and made up the volume up to 10.0 ml with 
the same to obtain concentration of 1000 µg/ml of the drug. It 
was  filtered  through  a  0.45  µ  membrane  filter.  The  stock 
solution was protected from light using aluminium foil and 
stored for 1 week at 4
0C and was found to be stable during 
this period. 
 
Construction of calibration curve 
Standard  stock  solution  were  accurately  transferred  into  a 
series of 10 ml calibrated volumetric flask and made up to the 
mark with methanol to obtain concentrations in the range of 
2-30  mcg/ml.  The  absorbance    of  resulting  solutions  was 
measured  at  318  nm  against  methanol  blank.    Calibration 
curve  was  prepared  by  plotting  the  absorbance  versus 
concentration of the drug.  
 
Assay Procedure  
20 Tablets of the product under study were weighed, crushed 
and  mixed  in  a  mortar  and  pestle.  A  portion  of  powder 
equivalent to the weight of 50 mg was accurately weighed 
and transferred to a dry 50 ml A-grade volumetric flask and 
40  ml  methanol  was  added.  The  volumetric  flask  was 
sonicated  for  15  min  to  effect  complete  dissolution  of 
satranidazole. It was cooled, made up to the mark by diluent 
and filtered through a 0.45 μm nylon filter. The absorbance 
of the resulting solution at the λmax was noted down and the 
content was determined.   
 
Conduct of stress studies  
The stress studies were carried out under the conditions of 
dry heat, UV-degradation, hydrolysis and oxidation. For dry 
heat  stress  testing,  solid drug  was  kept  in  Petri  dish  in  an 
oven at 105°C for 4 h and after cooling to room temperature, 
10  mg  of  SAT  was  weighed  and  transferred  to  a  10  mL 
calibrated flask, dissolved in methanol and diluted up to the 
mark  with the  same  solvent.  The  absorption  spectrum  was 
recorded from 200-400 nm. The UV degradation study was 
carried out by exposing the solution of SAT (20 µg/mL) to 
UV radiation in a UV chamber at shorter wavelength for 4 hr 
and the absorption spectrum was recorded. For  acid, alkali 
and oxidative degradation studies, 2 mL of 100 µg/mL SAT 
was  taken  separately  in  three  10  mL  calibrated  flasks  and 
mixed with 5 mL of 1M HCl (acid hydrolysis) or 1M NaOH 
(alkaline hydrolysis) or 3% H2O2 (oxidative degradation) and 
kept on hot water bath set at 80 °C for 2 h. Then, the solution 
was cooled to room temperature and diluted to the mark with 
methanol and the absorption spectra of the resulting solutions 
(20 µg/mL) were recorded. The absorbance values obtained 
in  stress  studies  were  compared  with  the  data  obtained  in 
calibration curve i.e. in the absence of forced degradation. 
 
Table 1: Evaluation of Intra-day and Inter-day precision 
 
Conc. (μg/ml))  Repeatability (intra-day precision)  Intermediate precision(inter-day) 
Mean Abs (n=3)  RSD (%)  Mean Abs (n=3)  RSD (%) 
12  0.485  0.62  0.481  0.79 
16  0.616  0.73  0.614  0.73 
20  0.769  0.54  0.771  0.49 
 
Table 2: Accuracy data as recovery 
 
Amount (%) of drug  
added to analyte 
Theoretical  content 
(μg/ml) 
conc. Found (μg/ml)  
± SD 
Recovery  
(%) 
RSD (%)  
n=3 
SEM 
0  10  9.91 ± 0.08  99.13  0.85  0.05 
80  18  18.07 ± 0.11  100.39  0.6  0.06 
100  20  20.12 ± 0.05  100.61  0.27  0.03 
120  22  21.81 ± 0.10  99.12  0.46  0.06 
 
Table 3: Ruggedness data 
 
Conc. (μg/ml))  RSD (%) n=3 
By Analyst 1  By Analyst 2  Instrument 1  Instrument 2 
12  0.62  0.71  0.75  0.81 
16  0.73  0.69  0.64  0.94 
20  0.54  0.62  0.72  0.87 
 
Table 4: Robustness data 
 
20 μg/mL of sample at different wavelengths  conc. Found (μg/ml)  Recovery (%)  RSD (%) 
317 nm  19.92  99.61  0.73 
20.11  100.53   
20.21  101.05   
318 nm  20.10  100.52  0.27 
20.08  100.39   
20.18  100.91   
319 nm  19.82  99.09  0.60 
19.97  99.87   
20.05  100.26   
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Table 5: Result of forced degradation study of Stranidazole 
 
Stress conditions  Concentration 
taken (μg/ml) 
% Recovery  Comments 
Neutral hydrolysis  20  99.61  Not degraded 
Acidic hydrolysis  20  100.65  Not degraded 
Alkali hydrolysis  20  5.47  Wavelength changed and  completely degraded 
Oxidation  20  99.35  Not degraded 
Heat at 100
0C  20  101.82  Not degraded 
UV radiation  20  98.44  Not degraded 
 
 
 
Figure 1. 3-(1-Methyl-5-nitroimidazol-2-yl)-1-(methylsulfonyl)imidazolidin-2-one 
 
 
 
Figure 2.  Absorption spectrum of Satranidazole (SAT) in methanol (20 μg/ml) 
 
 
 
Figure 3.  Linearity curve of Satranidazole in methanol 
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(a) 
 
 
(b) 
 
(c) 
 
 
(d) 
 
(e) 
 
 
(f) 
 
Figure 4.  Degradation study of SAT solution (a) treated with dry heat at 100
0C (b) oxidative degradation (c) UV radiation for shorter wavelength (d) 
treated with HCl (e) with NaOH (f) with NaOH after 24 hrs. 
 
RESULTS AND DISCUSSION 
Spectral characteristics 
The  absorption  spectrum  of  20  µg/mL  SAT  solution  in 
methanol was recorded between 200-400 nm and showed an 
absorption maximum (λmax) at 318 nm. At this wavelength 
methanol  had  insignificant  absorbance.  Therefore,  318  nm 
was  used  as  analytical  wavelength.  Figure.2  represents  the 
absorption spectra of SAT in methanol along with methanol 
blank. 
   
Method Validation 
Linearity 
A  series  of  standard  curves  were  prepared  over  a 
concentration range of 2 - 30 μg/ml by diluting the standard 
stock  solution  of  SAT  (1mg/ml)  in  diluents.  Triplicate 
determinations  on  each  of  the  concentration  levels  were 
analyzed.  The  data  from  drug  absorbance  versus  drug 
concentration  plots  were  treated  by  linear  least  square 
regression analysis and r
2 was found 0.999 (Figure.3).  
 
Precision 
Precision  was  determined  as  both  repeatability  and  
intermediate  precision,  in  accordance  with  ICH 
recommendations.  Repeatability  of  sample  absorbance  was 
determined as intra-day variation. Intermediate precision was 
determined  by  absorbance  measurement  of  inter-day 
variation.  For  both  intra-day  and  inter-day  variation  were 
performed at three different concentration levels in triplicate 
(Table 1).  
 
Accuracy, as Recovery 
Recovery  studies  by  the  standard  addition  method  were 
performed with a view to justify the accuracy of the proposed 
method. Previously analyzed samples SAT (10 μg/ml) were 
spiked  with  known  amount  of  standard  so  as  to  get  three 
different  levels  (80%,  100%  and  120%)  and  the  mixtures 
were analyzed by the proposed method. The experiment was 
performed  in  triplicate.  Recovery  (%),  RSD  (%)  were 
calculated for each concentration. The results of accuracy is 
given in Table 2. 
 
Ruggedness 
The ruggedness of the method was demonstrated by analysis 
of the samples as for precision study by a second analyst and 
other instrument. The RSD of the two sets of data indicates 
the ruggedness of the method. The difference was found to be 
non-significant (Table 3). 
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Robustness 
The robustness of the method was determined to assess the 
effect  of  small  but  deliberate  changes  of  the 
spectrophotometric conditions on the determination of SAT. 
The variation was difference in wavelength by ± 1 nm. The 
concentration of the solution analyzed was 20 μg/mL (Table 
4).  
 
Selectivity 
The proposed method was tested for selectivity by placebo 
containing mixture of commonly used tablet excipients, for 
example  starch,  microcrystalline  cellulose,  lactose,  talc, 
magnesium stearate, colloidal silicon dioxide, sodium starch 
glycollate  etc.  It  was  found  that  there  was  no  interference 
from  the  inactive  ingredients  as  indicated  by  the  blank 
absorbance. This result shows the selectivity of the method. 
 
Forced degradation of SAT 
Forced  degradation  studies  provide  an  indication  of  the 
stability-indicating  property  of  the  drug.  The  study  was 
carried out after subjecting SAT to dry heat treatment, UV-
degradation, acid and alkali hydrolysis; and oxidation.  The 
UV spectra of stress SAT samples which were subjected to 
dry  heat  treatment,  oxidation  and  UV-degradation  (Figure. 
4a,  4b  and  4c)  were  similar  to  that  of  the  standard  SAT 
sample (Figure.2) and it showed that SAT did not undergo 
degradation  under  these  conditions.  SAT  subjected  to  acid 
and  alkali  hydrolysis  showed  degradation,  since  the 
absorbance  values  obtained under these  stressed conditions 
(Figure.  4d,  4e)  were  smaller  than  the  original  value  of 
standard SAT sample (Figure.1). The degradation of SAT is 
much lesser under acidic environment in comparison to basic 
condition. The complete degradation observed under alkaline 
hydrolysis  after  24  hrs  (Figure.  4f).  The  %  recovery  data 
obtained in stress studies is presented in Table 5. 
 
CONCLUSION 
A  simple  and  sensitive  method  was  developed  for  the 
determination  of  satranidazole  in  its  tablet  dosage  form.  It 
can measure as low as 2.0 µg/ml with good accuracy. The 
proposed method could be used for routine quality control. 
Linear  regression  of  absorbance  on  concentration  gave  the 
equation y = 0.035x + 0.0644 with a correlation coefficient 
(r) of 0.9995. % relative standard deviation for intraday and 
interday precision, accuracy, ruggedness and robustness was 
found  to  be  less  than  2%.  The  higher  percentage  recovery 
value indicates that there is no interference of the excipients 
present in the formulation. The stability studies indicates that 
appreciable changes were observed by treating the drug with 
alkaline hydrolysis, however there was no appreciable change 
with acidic hydrolysis, UV light, thermal stress, oxidation.  
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